Evidence map›Paper›PMID 41416067›Full record

ArticleFrontiers in endocrinology2025

Guanine and pregnenolone sulfate are associated with incident type 2 diabetes in two independent populations.

Maria Barranco-Altirriba, Minerva Granado-Casas, Oscar Yanes, Jordi Capellades, Alexandra Junza, Josep Franch-Nadal, Joan Vendrell, Gemma Llauradó, Sergio Valdés, Eva García-Escobar and 11 more

Abstract read
In one paragraph

Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Maria Barranco-AltirribaDepartment of Endocrinology and Nutrition, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Minerva Granado-CasasCentro de Investigación Biomédica en red (CIBER) of Diabetes and Associated Metabolic Diseases (CIBERDEM), Instituto de Salud Carlos III (ISCIII), Barcelona, Spain.
Oscar YanesCentro de Investigación Biomédica en red (CIBER) of Diabetes and Associated Metabolic Diseases (CIBERDEM), Instituto de Salud Carlos III (ISCIII), Barcelona, Spain.
Jordi CapelladesCentro de Investigación Biomédica en red (CIBER) of Diabetes and Associated Metabolic Diseases (CIBERDEM), Instituto de Salud Carlos III (ISCIII), Barcelona, Spain.
Alexandra JunzaCentro de Investigación Biomédica en red (CIBER) of Diabetes and Associated Metabolic Diseases (CIBERDEM), Instituto de Salud Carlos III (ISCIII), Barcelona, Spain.
Josep Franch-NadalCentro de Investigación Biomédica en red (CIBER) of Diabetes and Associated Metabolic Diseases (CIBERDEM), Instituto de Salud Carlos III (ISCIII), Barcelona, Spain.
Joan VendrellCentro de Investigación Biomédica en red (CIBER) of Diabetes and Associated Metabolic Diseases (CIBERDEM), Instituto de Salud Carlos III (ISCIII), Barcelona, Spain.
Gemma LlauradóCentro de Investigación Biomédica en red (CIBER) of Diabetes and Associated Metabolic Diseases (CIBERDEM), Instituto de Salud Carlos III (ISCIII), Barcelona, Spain.
Sergio ValdésCentro de Investigación Biomédica en red (CIBER) of Diabetes and Associated Metabolic Diseases (CIBERDEM), Instituto de Salud Carlos III (ISCIII), Barcelona, Spain.
Eva García-EscobarCentro de Investigación Biomédica en red (CIBER) of Diabetes and Associated Metabolic Diseases (CIBERDEM), Instituto de Salud Carlos III (ISCIII), Barcelona, Spain.
Marcelino Bermúdez-LópezExperimental Medicine Department, University of Lleida, Lleida, Spain.
José Manuel ValdivielsoVascular and Renal Translational Research Group, Institut de Recerca Biomédica IRBLleida, Lleida, Spain.
Victor-Miguel López-LifanteFaculty of Medicine, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
Cecilia Herrero-AlonsoUnitat de Suport a la Recerca Metropolitana Nord, Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Mataró, Spain.
Mireia FalgueraDAP-Cat Group, Research Support Unit, Institut Universitari d'Investigació en Atenció Primària Jordi Gol, Barcelona, Spain.
Maria Belén VilanovaDAP-Cat Group, Research Support Unit, Institut Universitari d'Investigació en Atenció Primària Jordi Gol, Barcelona, Spain.
Ingrid ArteagaUnitat de Suport a la Recerca Metropolitana Nord, Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Mataró, Spain.
Pere Torán-MonserratUnitat de Suport a la Recerca Metropolitana Nord, Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Mataró, Spain.
Alexandre Perera-LlunaBioinformatics and Biomedical Signals Laboratory (B2SLab), Institut de Recerca i Innovació en Salut (IRIS), Universitat Politècnica de Catalunya, Barcelona, Spain.
Esmeralda CastelblancoDivision of Endocrinology, Metabolism and Lipid Research, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States.
Didac MauricioDepartment of Endocrinology and Nutrition, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Type 2 diabetes (T2D) is increasing its burden worldwide; therefore, research focused on its prediction and prevention is essential. Methods: We performed an untargeted metabolomics analysis using ultra high-performance liquid chromatography-mass spectrometry to discover metabolic biomarkers and biological pathways associated with incident T2D with a nested case-control design, followed by validation with targeted metabolomics in an independent cohort. In the discovery phase, plasma samples from 352 subjects (209 controls and 143 incident cases) were analyzed, collected with a mean (standard deviation) of 7.40 (0.76) years before they acquired the condition. Using this discovery phase cohort, six metabolites were identified using standards and were subsequently quantified in an independent validation phase cohort of 2,044 subjects (167 incident cases). Additionally, pathway enrichment was conducted in the discovery cohort. Results: Guanine, ecgonine, adenine, pregnenolone sulfate, phenyl sulfate, and citrulline were significantly associated with incident T2D in at least one of the analyses performed in the discovery phase. Among these, guanine, pregnenolone sulfate, and citrulline maintained their significant associations with incident T2D in the validation cohort. Additionally, several pathways were significantly altered, with nucleotide metabolism and ABC transporter pathways among the most consistently affected. Conclusion: We identified significant associations of guanine, pregnenolone sulfate, and citrulline with incident T2D.

Indexed as

Diabetes Mellitus, Type 2GuaninePregnenoloneAdultAgedBiomarkersCase-Control StudiesCohort StudiesFemaleHumansIncidenceMaleMetabolomicsMiddle AgedBiomarkersGuaninePregnenolonepregnenolone sulfateincident type 2 diabetesliquid chromatographymass spectrometrytargeted metabolomicsuntargeted metabolomics

Identifiers

PMID41416067
PMCPMC12708234

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.